Both men and women can suffer from sexual dysfunction, but there are no drugs available to treat the condition for women on the market currently. Flibanserin, also known as the little pink pill, is trying to change that. In 2010, the FDA denied Flibanserin of approval, and today Sprouts Pharmaceuticals, owner of the pill, is trying to appeal the decision.
If the decision is successfully appealed, Flibanserin could be available as early as next year. Learn how the pink pill can make a difference in women’s health and why it is important for women.
1) There are 25 drugs for male sexual dysfunction, but zero for women.
Currently, 25 approved drugs exist on the market for men suffering from some form of male sexual dysfunction, but there are zero available for women dealing with similar issues.
2) Flibanserin, or the Pink Pill, would be the first treatment for Hypoactive Sexual Desire Disorder (HSDD).
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction among women. There are no medical treatment options available for HSDD today, Cindy Whitehead, President and Chief Operating Officer of Sprout Pharmaceuticals, which owns Flibanserin, said on ABC’s “Nightline”.
3) As many as 1 in 10 women suffer from HSDD.
Women suffering from HSDD experience an absence or lack of sexual desires. While sexual dysfunction for men is visible, it can’t be seen with women. However, HSDD affects many women and can harm both their relationships as well as sexual well-being. “Nightline” reported that about 1 out of every 10 women suffers from HSDD, according to the International Journal of Women's Health.
4) Flibanserin is targeted to women’s sexual dysfunction issues.